All patients (n = 108) | |
---|---|
Age, years, mean ± SD | 45 ± 13 |
Male sex, n (%) | 67 (62) |
Race, n (%) | |
- White | 58 (54) |
- Asian | 15 (14) |
- Black | 14 (13) |
- Other | 20 (19) |
BMI, kg/m2, mean ± SD | 24.5 ± 5.5 |
Cause of ESRD, n (%) | |
- Diabetic nephropathy | 12 (11) |
- Glomerulonephritis | 44 (40) |
- Hypertensive nephrosclerosis | 7 (6) |
- Polycystic kidney disease | 10 (9) |
- Other | 35 (32) |
Type of renal replacement therapy prior to intensive hemodialysis, n (%) | |
- Chronic kidney disease not on dialysis | 32 (30) |
- Non-intensive hemodialysis | 39 (36) |
- Peritoneal dialysis | 11 (10) |
- Renal transplantation | 26 (24) |
Initial access type, n (%) | |
- CVC | 55 (51) |
- AVF | 43 (40) |
- AVG | 10 (9) |
Duration of ESKD, years, median (IQR) | 2 (0.3–12) |
Hours of dialysis per week, mean ± SD | 35 ± 7.3 |
Total follow up in years, mean ± SD | 4.0 ± 2.2 |
Time between echocardiograms in years, mean ± SD | 3.3 ± 2.0 |
Co-existing medical conditions, n (%) | |
- Diabetes | 27 (25) |
- Smoking history | 20 (19) |
- Hypertension | 93 (86) |
- Coronary artery disease | 10 (9) |
- Peripheral vascular disease | 6 (6) |
- Stroke | 6 (6) |
Baseline blood pressure therapy | |
- Number of antihypertensives, mean ± SD | 1.8 ± 1.3 |
- Patients on > 2 antihypertensives, n (%) | 28 (26) |
- RAAS blockade/CCB/β-blocker, % | 47/52/51 |
1-Year blood pressure therapy | |
- Number of antihypertensives, mean ± SD | 0.8 ± 1.0 |
- Patients on > 2 antihypertensives, n (%) | 6 (6) |
- RAAS blockade/CCB/β-blocker, % | 17/17/43 |